Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Izervay
Pharma
Apellis stock price slid 10% despite 'robust' growth of Syfovre
Despite the expansion of Syfovre in geographic atrophy ahead of analysts' expectations, Apellis' stock price has dropped 30% so far this year.
Angus Liu
May 8, 2024 11:30am
Apellis working through continued challenges with Syfovre launch
Feb 28, 2024 11:53am
Astellas raises expectations for Padcev, lowers them for Veozah
Feb 5, 2024 10:57am
Apellis counters Izervay results with long-term data of its own
Nov 6, 2023 3:53pm
Apellis' stumbling GA drug Syfovre shows signs of recovery
Oct 5, 2023 11:22am
Astellas touts 2-year trial of Izervay, but questions remain
Sep 19, 2023 11:32am
